These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 31853314)

  • 1. miR-31-5p may enhance the efficacy of chemotherapy with Taxol and cisplatin in TNBC.
    Shen X; Lei J; Du L
    Exp Ther Med; 2020 Jan; 19(1):375-383. PubMed ID: 31853314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
    Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
    Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-1207-5p regulates the sensitivity of triple-negative breast cancer cells to Taxol treatment via the suppression of LZTS1 expression.
    Hou X; Niu Z; Liu L; Guo Q; Li H; Yang X; Zhang X
    Oncol Lett; 2019 Jan; 17(1):990-998. PubMed ID: 30655858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.
    Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X
    Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of miR-155-5p enhances the anti-tumor effect of cetuximab on triple-negative breast cancer cells via inducing cell apoptosis and pyroptosis.
    Xu W; Song C; Wang X; Li Y; Bai X; Liang X; Wu J; Liu J
    Aging (Albany NY); 2021 Jan; 13(1):228-240. PubMed ID: 33472170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of microRNA-620 facilitates the resistance of triple negative breast cancer cells to gemcitabine treatment by targeting DCTD.
    Wu C; Zhao A; Tan T; Wang Y; Shen Z
    Exp Ther Med; 2019 Jul; 18(1):550-558. PubMed ID: 31258693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-153-5p Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Paclitaxel by Inducing G2M Phase Arrest.
    Wang Y; Wu N; Zhang J; Wang H; Men X
    Onco Targets Ther; 2020; 13():4089-4097. PubMed ID: 32494162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-33a-5p overexpression sensitizes triple-negative breast cancer to doxorubicin by inhibiting eIF5A2 and epithelial-mesenchymal transition.
    Guan X; Gu S; Yuan M; Zheng X; Wu J
    Oncol Lett; 2019 Dec; 18(6):5986-5994. PubMed ID: 31788073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combined therapy of miR-383-5p restoration and paclitaxel for treating MDA-MB-231 breast cancer.
    Dastmalchi N; Azarbarzin S; Safaralizadeh R; Khojasteh SMB; Shadbad MA; Amini M; Baghbanzadeh A; Asl ER; Baghbani E; Lotfinejad P; Baradaran B
    Med Oncol; 2021 Nov; 39(1):9. PubMed ID: 34761351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of miR-483-5p improves the proliferation, invasion and inflammatory response of triple-negative breast cancer cells by targeting SOCS3.
    Ren J; Xu G; Sun H; Lin T; Xu S; Zhao Y
    Exp Ther Med; 2021 Oct; 22(4):1047. PubMed ID: 34434261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
    Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
    BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-497 inhibits proliferation and invasion in triple-negative breast cancer cells via YAP1.
    Li Y; Hua K; Jin J; Fang L
    Oncol Lett; 2021 Aug; 22(2):580. PubMed ID: 34122631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression.
    Wu J; Chen H; Ye M; Wang B; Zhang Y; Sheng J; Meng T; Chen H
    Biomed Pharmacother; 2019 Jul; 115():108869. PubMed ID: 31028999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells.
    Li S; Li Q; Lü J; Zhao Q; Li D; Shen L; Wang Z; Liu J; Xie D; Cho WC; Xu S; Yu Z
    Front Genet; 2019; 10():1278. PubMed ID: 32010177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer].
    Ma T; Zhang J; Wu J; Tang J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 May; 39(5):488-95. PubMed ID: 24921394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
    Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
    BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-362-5p enhances the cisplatin sensitivity of gastric cancer cells by targeting suppressor of zeste 12 protein.
    Wei X; Gao M; Ahmed Y; Gao M; Liu W; Zhang Y; Xie X; Zhao Q; Wang H; Gu K
    Oncol Lett; 2019 Aug; 18(2):1607-1616. PubMed ID: 31423228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A thiosemicarbazone derivative induces triple negative breast cancer cell apoptosis: possible role of miRNA-125a-5p and miRNA-181a-5p.
    El Majzoub R; Fayyad-Kazan M; Nasr El Dine A; Makki R; Hamade E; Grée R; Hachem A; Talhouk R; Fayyad-Kazan H; Badran B
    Genes Genomics; 2019 Dec; 41(12):1431-1443. PubMed ID: 31541355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM).
    Fan X; Zhou S; Zheng M; Deng X; Yi Y; Huang T
    Biomed Pharmacother; 2017 Apr; 88():507-514. PubMed ID: 28126676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNFAIP8 Promotes Cisplatin Chemoresistance in Triple-Negative Breast Cancer by Repressing p53-Mediated miR-205-5p Expression.
    Ma HY; Li Y; Yin HZ; Yin H; Qu YY; Xu QY
    Mol Ther Nucleic Acids; 2020 Dec; 22():640-656. PubMed ID: 33230463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.